Good綜合征合并新型冠狀病毒持續感染、肺腺癌一例并文獻復習_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

樊俊玲 ,  陳亞娟

重慶醫科大學附屬第一醫院呼吸與危重癥醫學科（重慶 400016）;

Corresponding?author：

陳亞娟, Email: yajuanchencqmu@sina.com

Keywords：

Good綜合征; 新型冠狀病毒感染; 肺腺癌

DOI：

10.7507/1671-6205.202406128

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的通過本病例及文獻復習以增加對Good綜合征合并新型冠狀病毒感染（coronavirus disease 2019，COVID-19）及免疫缺陷與腫瘤發生的認知，為Good綜合征合并COVID-19的治療提供參考。方法回顧我院診治的1例Good綜合征合并新型冠狀病毒（新冠病毒）持續感染、肺腺癌患者的臨床資料，復習既往Good綜合征合并COVID-19相關文獻，總結其臨床特征及治療方法。結果患者男，61歲，反復發熱、咳嗽6個月余。胸部CT提示雙肺多發炎癥，右肺上葉前段胸膜下混合磨玻璃結節，前縱隔腫塊；新冠病毒核酸檢測陽性，新冠病毒IgG+IgM抗體檢測陰性。給予康復期血漿療法后患者明顯好轉，核酸檢測呈陰性，抗體檢測呈陽性，后于我院手術切除縱隔及肺部病變，最終明確診斷為Good綜合征合并浸潤性肺腺癌。復習文獻，共有17例Good綜合征合并COVID-19個案報道，男性相較于女性發病率更高，胸腺瘤主要病理類型為AB型（55.6%），大部分患者給予了免疫球蛋白治療，但仍有7例患者死亡，死亡原因大多為呼吸衰竭、膿毒性休克。結論對于有胸腺瘤病史伴反復感染的患者臨床醫生應想到Good綜合征的可能，早診斷早治療，同時對存在免疫缺陷、胸腺瘤的患者要警惕惡性腫瘤的發生。

Citation： 樊俊玲, 陳亞娟. Good綜合征合并新型冠狀病毒持續感染、肺腺癌一例并文獻復習. Chinese Journal of Respiratory and Critical Care Medicine, 2025, 24(3): 197-201. doi: 10.7507/1671-6205.202406128 Copy

1.	Tavakol M, Mahdaviani SA, Ghaemi MR, et al. Good’s syndrome-association of the late onset combined immunodeficiency with thymoma: review of literature and case report. Iran J Allergy Asthma Immunol, 2018, 17(1): 85-93.
2.	Yang C, Zhao H, Espín E, et al. Association of SARS-CoV-2 infection and persistence with long COVID. Lancet Respir Med, 2023, 11(6): 504-506.
3.	Pozzi MR, Baronio M, Janetti MB, et al. Fatal SARS-CoV-2 infection in a male patient with Good’s syndrome. Clin Immunol, 2021, 223: 108644.
4.	London J, Boutboul D, Lacombe K, et al. Severe COVID-19 in patients with B cell alymphocytosis and response to convalescent plasma therapy. J Clin Immunol, 2021, 41(2): 356-361.
5.	López AL, Torre MG, Paolini MV, et al. COVID-19 in adults with antibody deficiencies. Medicina (B Aires), 2021, 81(3): 478-481.
6.	Cosesquius ML, Lópezmontesinos I, Gimenomartinez R, et al. Severe COVID-19 pneumonia in Good syndrome with a favorable outcome. Clin Immunol, 2022, 235: 108789.
7.	Duarte M, Faria L, Patronillo C, et al. A case of severe COVID-19 in a patient with Good’s syndrome. Eur J Case Rep Intern Med, 2021, 8(10): 002976.
8.	Lindahl H, Smith CIE, Bergman P. COVID-19 in a patient with Good’s syndrome and in 13 patients with common variable immunodeficiency. Clin Immunol Commun, 2021, 1: 20-24.
9.	Meena M, Kumar KS, Rajawat GS, et al. Five times reactivation of COVID-19 in a patient with thymoma. J Assoc Physicians India, 2022, Feb,70(2): 11-12.
10.	Maldonado-domínguez ED, Farrill-romanillos PM. Patient with Good’s syndrome and COVID-19: report of a clinical case. Rev Med Inst Mex Seguro Soc, 2022, 60(4): 474-479.
11.	Wee LE, Tan JY, Oon LLE, et al. Relapsing COVID-19 infection as a manifestation of Good syndrome: a case report and literature review. Int J Infect Dis, 2023, 129: 236-239.
12.	Berzenji L, Yogeswaran SK, Snoeckx A, et al. Good’s syndrome and COVID-19: case report and literature review. Mediastinum, 2023, 7: 5.
13.	Cerezoli MT, Prats JAGG, Medeiros AK, et al. Clinical and radiological improvement of protracted COVID-19 and Good syndrome secondary to advanced thymoma. Pulmonology, 2022, 28(6): 472-475.
14.	楊露露, 黃麗婷, 任思穎, 等. Good綜合征合并新型冠狀病毒感染4例并文獻復習. 中華結核和呼吸雜志, 2024, 47(5): 430-436. DOI: 10.3760/cma.j.cn112147-20230923 -00192.
15.	Tabarsi P, Hemmatian M, Moradi M. Long COVID‐19 leading to Good’s syndrome diagnosis: a clinical case‐report and literature review. Clin Case Rep, 2024, 12(6): e8962.
16.	Guevara-hoyer K, Fuentes-antrás J, Calatayudgastardi J, et al. Immunodeficiency and thymoma in Good syndrome: two sides of the same coin. Immunol Lett, 2021, 231: 11-17.
17.	Chen YD, Wen ZH, Wei B, et al. Clinicopathologic features of Good’s syndrome: two cases and literature review. Open Med (Wars), 2021, 16(1): 532-539.
18.	Wang CH, Chan ED, Perng CL, et al. Intravenous immunoglobulin replacement therapy to prevent pulmonary infection in a patient with Good’s syndrome. J Microbiol Immunol Infect, 2015, 48(2): 229-232.
19.	Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science, 2015, 348(6230): 69-74.
20.	Oskara H. Immunodeficiency and cancer predisposition revisited: embedding two closely related concepts into an integrative conceptual framework. Frontiers in immunology, 2019, 9.
21.	Eilber FR, Morton DL. Impaired immunologic reactivity and recurrence following cancer surgery. Cancer. 1970, 25(2): 362-367.
22.	Mayor PC, Eng KH, Singel KL, et al. Cancer in primary immunodeficiency diseases: cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol, 2018, 141(3): 1028-1035.
23.	楊寧寧, 劉紹霞. AB型胸腺瘤合并肺腺癌1例. 臨床腫瘤學雜志, 2016, 21(4): 381-382.
24.	Patella M, Anile M, Vitolo D, et al. Synchronous B3 thymoma and lung bronchoalveolar carcinoma. Interact Cardiovasc Thorac Surg, 2011, 12(1): 75-76.

1. Tavakol M, Mahdaviani SA, Ghaemi MR, et al. Good’s syndrome-association of the late onset combined immunodeficiency with thymoma: review of literature and case report. Iran J Allergy Asthma Immunol, 2018, 17(1): 85-93.
2. Yang C, Zhao H, Espín E, et al. Association of SARS-CoV-2 infection and persistence with long COVID. Lancet Respir Med, 2023, 11(6): 504-506.
3. Pozzi MR, Baronio M, Janetti MB, et al. Fatal SARS-CoV-2 infection in a male patient with Good’s syndrome. Clin Immunol, 2021, 223: 108644.
4. London J, Boutboul D, Lacombe K, et al. Severe COVID-19 in patients with B cell alymphocytosis and response to convalescent plasma therapy. J Clin Immunol, 2021, 41(2): 356-361.
5. López AL, Torre MG, Paolini MV, et al. COVID-19 in adults with antibody deficiencies. Medicina (B Aires), 2021, 81(3): 478-481.
6. Cosesquius ML, Lópezmontesinos I, Gimenomartinez R, et al. Severe COVID-19 pneumonia in Good syndrome with a favorable outcome. Clin Immunol, 2022, 235: 108789.
7. Duarte M, Faria L, Patronillo C, et al. A case of severe COVID-19 in a patient with Good’s syndrome. Eur J Case Rep Intern Med, 2021, 8(10): 002976.
8. Lindahl H, Smith CIE, Bergman P. COVID-19 in a patient with Good’s syndrome and in 13 patients with common variable immunodeficiency. Clin Immunol Commun, 2021, 1: 20-24.
9. Meena M, Kumar KS, Rajawat GS, et al. Five times reactivation of COVID-19 in a patient with thymoma. J Assoc Physicians India, 2022, Feb,70(2): 11-12.
10. Maldonado-domínguez ED, Farrill-romanillos PM. Patient with Good’s syndrome and COVID-19: report of a clinical case. Rev Med Inst Mex Seguro Soc, 2022, 60(4): 474-479.
11. Wee LE, Tan JY, Oon LLE, et al. Relapsing COVID-19 infection as a manifestation of Good syndrome: a case report and literature review. Int J Infect Dis, 2023, 129: 236-239.
12. Berzenji L, Yogeswaran SK, Snoeckx A, et al. Good’s syndrome and COVID-19: case report and literature review. Mediastinum, 2023, 7: 5.
13. Cerezoli MT, Prats JAGG, Medeiros AK, et al. Clinical and radiological improvement of protracted COVID-19 and Good syndrome secondary to advanced thymoma. Pulmonology, 2022, 28(6): 472-475.
14. 楊露露, 黃麗婷, 任思穎, 等. Good綜合征合并新型冠狀病毒感染4例并文獻復習. 中華結核和呼吸雜志, 2024, 47(5): 430-436. DOI: 10.3760/cma.j.cn112147-20230923 -00192.
15. Tabarsi P, Hemmatian M, Moradi M. Long COVID‐19 leading to Good’s syndrome diagnosis: a clinical case‐report and literature review. Clin Case Rep, 2024, 12(6): e8962.
16. Guevara-hoyer K, Fuentes-antrás J, Calatayudgastardi J, et al. Immunodeficiency and thymoma in Good syndrome: two sides of the same coin. Immunol Lett, 2021, 231: 11-17.
17. Chen YD, Wen ZH, Wei B, et al. Clinicopathologic features of Good’s syndrome: two cases and literature review. Open Med (Wars), 2021, 16(1): 532-539.
18. Wang CH, Chan ED, Perng CL, et al. Intravenous immunoglobulin replacement therapy to prevent pulmonary infection in a patient with Good’s syndrome. J Microbiol Immunol Infect, 2015, 48(2): 229-232.
19. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science, 2015, 348(6230): 69-74.
20. Oskara H. Immunodeficiency and cancer predisposition revisited: embedding two closely related concepts into an integrative conceptual framework. Frontiers in immunology, 2019, 9.
21. Eilber FR, Morton DL. Impaired immunologic reactivity and recurrence following cancer surgery. Cancer. 1970, 25(2): 362-367.
22. Mayor PC, Eng KH, Singel KL, et al. Cancer in primary immunodeficiency diseases: cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol, 2018, 141(3): 1028-1035.
23. 楊寧寧, 劉紹霞. AB型胸腺瘤合并肺腺癌1例. 臨床腫瘤學雜志, 2016, 21(4): 381-382.
24. Patella M, Anile M, Vitolo D, et al. Synchronous B3 thymoma and lung bronchoalveolar carcinoma. Interact Cardiovasc Thorac Surg, 2011, 12(1): 75-76.

Chinese Journal of Respiratory and Critical Care Medicine

Good綜合征合并新型冠狀病毒持續感染、肺腺癌一例并文獻復習

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content